Daewoong Pharma
KRX:069620
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
99 900
150 000
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
Abbvie Inc
NYSE:ABBV
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Realty Income Corp
NYSE:O
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Daewoong Pharma
Daewoong Pharma
Other Current Liabilities
Daewoong Pharma
Other Current Liabilities Peer Comparison
000100
326030
128940
Competitive Other Current Liabilities Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Daewoong Pharma
KRX:069620
|
Other Current Liabilities
₩165.1B
|
CAGR 3-Years
10%
|
CAGR 5-Years
14%
|
CAGR 10-Years
16%
|
|
|
Yuhan Corp
KRX:000100
|
Other Current Liabilities
₩250.6B
|
CAGR 3-Years
18%
|
CAGR 5-Years
13%
|
CAGR 10-Years
15%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Other Current Liabilities
₩110.9B
|
CAGR 3-Years
76%
|
CAGR 5-Years
74%
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Other Current Liabilities
₩130.6B
|
CAGR 3-Years
26%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Other Current Liabilities
₩23.1B
|
CAGR 3-Years
12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
12%
|
|
C
|
Celltrion Pharm Inc
KOSDAQ:068760
|
Other Current Liabilities
₩24.4B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
13%
|
CAGR 10-Years
23%
|
See Also
What is Daewoong Pharma's Other Current Liabilities?
Other Current Liabilities
165.1B
KRW
Based on the financial report for Jun 30, 2024, Daewoong Pharma's Other Current Liabilities amounts to 165.1B KRW.
What is Daewoong Pharma's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
16%
Over the last year, the Other Current Liabilities growth was 13%. The average annual Other Current Liabilities growth rates for Daewoong Pharma have been 10% over the past three years , 14% over the past five years , and 16% over the past ten years .
You don't have any saved screeners yet
